Nucleic acid vaccines
First Claim
Patent Images
1. A nucleic acid vaccine, comprising:
- one or more RNA polynucleotides having an open reading frame encoding a hemagglutinin protein selected from H1, H7 and H10 wherein the hemagglutinin protein is derived from a strain of Influenza A virus, wherein the RNA polynucleotide includes a chemical modification and a pharmaceutically acceptable carrier or excipient, formulated within a lipid nanoparticle, wherein the lipid nanoparticle has about 20-60 mol % ionizable cationic lipid;
about 5-25 mol % non-cationic lipid;
about 25-55 mol % sterol; and
about 0.5-15 mol % PEG-modified lipid.
2 Assignments
0 Petitions
Reexamination
Accused Products
Abstract
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (NAVs) comprising polynucleotide molecules encoding one or more antigens.
-
Citations
26 Claims
-
1. A nucleic acid vaccine, comprising:
one or more RNA polynucleotides having an open reading frame encoding a hemagglutinin protein selected from H1, H7 and H10 wherein the hemagglutinin protein is derived from a strain of Influenza A virus, wherein the RNA polynucleotide includes a chemical modification and a pharmaceutically acceptable carrier or excipient, formulated within a lipid nanoparticle, wherein the lipid nanoparticle has about 20-60 mol % ionizable cationic lipid;
about 5-25 mol % non-cationic lipid;
about 25-55 mol % sterol; and
about 0.5-15 mol % PEG-modified lipid.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
-
23. A nucleic acid immunogenic composition, comprising:
one or more RNA polynucleotides having an open reading frame encoding a hemagglutinin protein selected from H1, H7 and H10 wherein the hemagglutinin protein is derived from a strain of Influenza A virus, wherein the RNA polynucleotide includes a chemical modification and a pharmaceutically acceptable carrier or excipient, formulated within a lipid nanoparticle, wherein the lipid nanoparticle has about 20-60 mol % ionizable cationic lipid;
about 5-25 mol % non-cationic lipid;
about 25-55 mol % sterol; and
about 0.5-15 mol % PEG-modified lipid.- View Dependent Claims (24, 25, 26)
Specification